Zentalis Announces Presentation of Positive Phase 1b Data

Strong anti-tumor activity shown in a platinum-resistant ovarian cancer population, with a confirmed ORR of 50.0% and mPFS of 7.4 months in combination...

Related Keywords

San Diego ,California ,United States ,New York ,Kimberly Blackwell ,Premalh Thaker ,Joyce Liu ,Emily White ,Danielle Cantey ,Division Of Gynecologic Oncology ,Zentalis Pharmaceuticals ,Nasdaq ,Gynecological Oncology Clinical Research ,Dana Farber Cancer Institute ,Washington University School Of Medicine ,Solebury Strategic Communications ,Linkedin ,Exchange Commission ,Pharmaceuticals Inc ,Chief Executive Officer ,Safety Results ,Frequent Grade ,Associate Chief ,Clinical Research ,Gynecologic Oncology ,Dana Farber Cancer ,Washington University School ,Board Number ,Discussion Session Date ,Presentation Number ,Integrated Discovery Engine ,Securities Litigation Reform Act ,Nasdaq Zntl ,